(AND) Andor Technology
Summary
Buy UK shares for just £1.50. No hidden charges, admin or inactivity fees
|
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||
| Headline | Source | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||||||||||||||||||||||||
| Tue 13:55 | RNS |
|||||||||||||||||||||||||||||||||||||
|
RNS Number : 9628W Andor Technology plc 07 February 2012
Andor Technology plc 06 February 2012
Andor Technology plc ("Andor" or the "Company")
Directorate Change
Andor Technology plc (AND.L), a global leader in the development and manufacture of high performance scientific digital cameras for academic, industrial and government applications, announces that Aislinn Rice has today tendered her resignation as Sales Director for Rest of World and will take up a new part-time role as Head of Research Sales. Christopher Calling, who has held the position of Global Sales Director since June 2011 during Aislinn's maternity leave, will assume this role on a permanent basis with immediate effect.
Commenting, Colin Walsh, Chairman said: "We would like to thank Aislinn for her great contribution to both the Company and the plc board and we are delighted that, despite the change in circumstance, Aislinn will remain a key member of the global sales team."
For further information please contact:
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||
| Fri 16:19 | RNS |
|||||||||||||||||||||||||||||||||||||
|
RNS Number : 8071W Andor Technology plc 03 February 2012 BLOCKLISTING SIX MONTHLY RETURN
To: The FSA
Date: 03 February 2012
1. Name of applicant:
2. Name of scheme
3. Period of return:
4. Balance under scheme from previous return:
5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return
6. Number of securities issued/allotted under scheme during period:
7 Balance under scheme not yet issued/allotted at end of period
8. Number and class of securities originally listed and the date of admission
9. Total number of securities in issue at the end of the period
BLOCKLISTING SIX MONTHLY RETURN
To: The FSA
Date: 03 February 2012
1. Name of applicant:
2. Name of scheme
3. Period of return:
4. Balance under scheme from previous return:
5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return
6. Number of securities issued/allotted under scheme during period:
7 Balance under scheme not yet issued/allotted at end of period
8. Number and class of securities originally listed and the date of admission
9. Total number of securities in issue at the end of the period
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||
| Fri 11:21 | RNS |
|||||||||||||||||||||||||||||||||||||
|
RNS Number : 7677W Andor Technology plc 03 February 2012
Andor Technology plc 03 February 2012
Andor Technology plc ("Andor" or the "Company")
Director Shareholdings
Andor Technology plc (AND.L), a global leader in the development and manufacture of high performance scientific digital cameras for academic, industrial and government applications, announces that on 2 February 2012, Mr Christopher Calling, the Company's US Sales Director, exercised 175,000 ordinary shares of 2p each under the Enterprise Management Incentive Scheme. On 2 February 2012, Mr Calling sold 160,000 ordinary shares of 2p each in the Company ("Ordinary Shares") at a price of 555 pence per share. This takes Mr Calling's total shareholding to 15,250 Ordinary Shares representing 0.04% of the Company's issued share capital.
The Company also announces that on 2 February 2012, Mr Conor Walsh, the Company's Chief Executive Officer, exercised and sold 40,000 ordinary shares of 2p each under the Enterprise Management Incentive Scheme at a price of 555 pence per share. This takes Mr Walsh's total holding to 50,000 Ordinary Shares representing 0.16% of the Company's issued share capital.
For further information please contact:
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||
| 19-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||
|
RNS Number : 8823V Andor Technology plc 19 January 2012
19 January 2012
ANDOR TECHNOLOGY PLC("Andor")
Annual Report & Accounts and Notice of AGM
Andor Technology plc (AND.L), is pleased to announce that it has posted to shareholders its Annual Report & Accounts for the year ended 30 September 2011 and Notice of Annual General Meeting for 2012 ("AGM").
The Company will be holding the AGM at 7 Millennium Way, Springvale Business Park, Belfast, BT12 7AL on 21 February 2012 at 12.00 pm.
Copies of the Annual Report & Accounts and Notice of Annual General Meeting are available for viewing on the Company's website www.andor.com.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||
| Result Pages: 1 | ||||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| 10-01-12 | ||||
|
|
||||
|
|
||||
|
Andor Technology plc : Pioneering publication reports first ratiometric, single-protein red fluorescent pH sensor in live neurons
Harvard Medical School team uses Andor Revolution DSD confocal for simultaneous measurement of intracellular pH and ATP in live cells Belfast, Northern Ireland, 10 January 2011 http://bit.ly/Aw8Ife |
||||
| 07-12-11 | ||||
|
|
||||
|
|
||||
|
12/07/2011 | 07:36 am
Andor Technology plc : Andor pairing can tell their Ardberg from their Edradour http://bit.ly/rrwq7X St Andrew's University researchers use laser-based near-infrared (NIR) spectroscopy to characterise whiskies and identify fakes 7th December 2011, Belfast, UK: If you can't tell your Bruichladdich from your Irn-Bru, or your Glenfiddich from your Glenmorangie, help is at hand from the physics department at St Andrews University. Praveen Ashok, Kishan Dholakia and Bavishna Praveen of the optical manipulation group have developed a microfluidic device that can not only detect counterfeit whisky samples but also characterise genuine samples by brand, age and, even, cask. Quality standardisation for Scotch whisky is assessed using alcohol content, colour consistency and flavour. Low alcohol content is a primary indicator of fake whisky but the distinctive flavour, which is determined by its congener profile, is very difficult to mimic. This profile is governed by organic compounds formed during fermentation and during maturation in wooden casks. Amounting to less than 1% of the total volume, these include organic acids, higher order alcohols, esters, and aldehydes and wood extracts, such as tannin, acid and colouring matters. The team used an alignment-free, optical fibre based, optofluidic chip to analyse 20 µL samples of commercially available single malt whiskies using Near Infrared (NIR) spectroscopy. No sample preparation was involved, variation due to ethanol evaporation was eliminated by the confinement within the microfluidic channel and the analysis time of was approximately two seconds. Raman and fluorescence spectra were recorded by an Andor Shamrock SR-303i spectrometer equipped with an Andor Newton DU920P BR-DD back-illuminated, thermoelectrically-cooled CCD camera. "The Raman spectra of the whisky samples is dominated by peaks corresponding to 40% ethanol and our results clearly demonstrate that the alcohol content may be predicted to a probability of more than 99%, enough to rapidly weed out the majority of fakes" says Praveen Ashok. "Although the congener components could not be distinguished from differences in the Raman peaks, the broad fluorescence background is markedly different for different types of whisky due to the variation in congener profiles. The result is successful classification of whiskies based upon their age, origin and cask - a skill few human palettes can match. "We chose the Andor analytical instruments due to the high sensitivity of the DU920P BR-DD CCD camera and the small form factor of the Shamrock SR-303i spectrometer. While its performance is every bit as good as a bench-top system, the Shamrock's compact size and low weight lent it a degree of portability as well. This was important to us as we wanted to demonstrate the potential of a hand-held device that could be used by distilleries to quality control their production by benchmarking against a known standard. The same hand-held instrument could also be used to test for counterfeit whisky bottles and confidently deliver reliable results in seconds," concludes Ashok. "The maintenance-free, deep Thermo-Electric cooling and USB connectivity of the Newton Deep-Depletion platform enables access to the highest NIR sensitive detection, not only in Research labs but also in challenging industrial environments," according to Antoine Varagnat, Product specialist at Andor. "When combining the Shamrock 303 USB spectrograph with their novel Raman-based micro-fluidics system, Ashok's team were able to successfully demonstrate a very sensitive and accurate setup for the rapid characterization and sorting of liquids, This also enabled them to identify counterfeit lots of potentially valuable spirits in an industrial environment. This powerful Raman micro-fluidics technique will be of great interest for the liquid-processing industry in general, but this is also great news for Whisky aficionados around the wor |
||||
| 05-12-11 | ||||
|
|
||||
|
|
||||
|
12/05/2011 | 11:42 am
http://www.4-traders.com/ANDOR-TECHNOLOGY-PLC-4004967/news/ANDOR-TECHNOLOGY-PLC-Non-invasive-instrument-for-skin-cancer-screening-demonstrated-13919984/ Andor Technology plc : Non-invasive instrument for skin cancer screening demonstrated Andor Newton camera powers combined RS-OCT probe capable of both morphological and biochemical characterization of skin cancers Skin cancer is the most common form of human cancer with annual rates continuing to climb from their current estimate of just over three million new cases each year. Although all skin cancers share the likelihood of a favourable outcome if early diagnosis and complete resection are achieved, diagnosis is invasive, subjective, lengthy and expensive involving expert visual inspection, biopsy and histopathology. Now, a joint US-Dutch team under the direction of Anita Mahadevan-Jansen, Vanderbilt University, US, has developed a non-invasive probe capable of both morphological and biochemical characterization of skin cancers. The portable instrument combines a Raman spectroscopy (RS) system with an Optical Coherence Tomography (OCT) device and enables sequential acquisition of co-registered OCT and RS data sets. An Andor high resolution, near-infrared-enhanced Newton camera was chosen as the core element of the Raman diagnosis module. The probe will screen large areas of skin up to 15 mm wide to a depth of 2.4 mm with OCT to visualize microstructural irregularities and perform an initial morphological analysis of lesions. The OCT images are then used to identify locations to acquire biochemically specific Raman spectra. "Due to the inherently weak nature of Raman scattering and the relatively intense background autofluorescence from tissue, collection efficiency is a critical factor in the design of clinical RS probes," says Chetan A. Patil, Vanderbilt University, US. "Unlike confocal approaches that emphasize axial resolution, our probe is designed to prioritize collection efficiency. The high sensitivity of the Andor Newton CCD's back-illuminated, deep-depletion, thermo-electrically cooled design is well suited to the stringent demands of in vivo Raman spectroscopy. "Having demonstrated the clinical potential of the RS-OCT instrument to rapidly screen at risk patients, we are continuing to develop the dual-modal technique for other applications where non-invasive assessment of both microstructure and biochemical composition are critical to accurate assessment of pathology. The Labview software development kit, which is supplied with the camera and supported directly by Andor, was crucial in the development of our first probe and in our on-going research," concludes Patil. According to Antoine Varagnat, Product Specialist at Andor, "With its high sensitivity in the NIR enabled by high Quantum Efficiency and deep TE-cooling interface, the Newton Deep-Depletion CCD platform is just the right detector for demanding clinical NIR spectral diagnosis. One also gets the benefit of long-lasting detection performance and reliability with Andor's UltraVac vacuum technology, alongside high speed acquisitions and ease of integration." Andor's modular Spectroscopy solutions encompass a wide range of high performance CCD, ICCD, EMCCD and InGaAs array detectors, as well as a comprehensive range of Research-grade spectrograph platforms. To learn more about the Newton camera series and their use in spectroscopy, please visit the Andor website . |
||||
| 28-11-11 | ||||
|
|
||||
|
|
||||
|
http://www.investorschronicle.co.uk/2011/11/28/shares/news-and-analysis/andor-marches-on-2p3cMNM5Jg5o69UITvKbvN/article.html
Andor marches on By Graeme Davies, 28 November 2011 Scientific imaging manufacturer Andor Technology maintained its enviable growth record by registering an impressive 14th consecutive year of compound sales growth of over 30 per cent. Andor has benefited from continued growth in its core high-end markets, where it's taking market share, coupled with an expansion of its product range into mid-range products. This resulted in growth of at least 20 per cent in every business segment and region in which Andor sells. The group enjoyed particular success in sales of bespoke systems, which more than doubled and now account for 22 per cent of total revenues. The systems offering was boosted by two acquisitions last year. Systems sales are lower margin than product or original equipment manufacturer (OEM) sales, which meant that overall gross margins dipped a little although chief executive Conor Walsh doesn't expect systems to grow beyond 30 per cent of revenues as it has the potential to cannibalise other parts of the business. Andor's order book grew £400,000 on last year to £13.8m. But there's relatively limited visibility in the order book and Mr Walsh admitted there are signs of nervousness, particularly in the US OEM market where there has been some de-stocking of inventories. Broker finnCap expects adjusted pre-tax profit of £11.5m for 2012, and EPS of 28.6p (from £9.7m and 24.8p in 2011 ). ANDOR TECHNOLOGY (AND) ORD PRICE: 550p MARKET VALUE: £168.8m TOUCH: 545-554p 12-MONTH HIGH: 690p LOW: 361p DIVIDEND YIELD: nil PE RATIO: 25 NET ASSET VALUE: 128p* NET CASH: £12.7m Year to 30 Sep Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2007 21.3 1.28 4.37 nil 2008 24.7 1.51 4.22 nil 2009 33.1 4.61 14.4 nil 2010 42.7 5.81 15.7 nil 2011 57.4 8.74 21.6 nil % change +34 +50 +38 - Ex-div: - Payment: - *Includes intangible assets of £16.6m, or 54p a share IC VIEW: A forward PE ratio of 19 isn't cheap, but Andor's new product launches and increased market penetration bode well for 2012 despite the challenging wider economic conditions. Long-term good value. |
||||
|
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
Markets: FTSE 100 in the black as Bank announces more QEEditor's Pick:
View from the top: Tangiers Petroleum interviewEditor's Pick:
Greece strikes bail-out agreementEditor's Pick:
Bank announces £50bn quantitative easing packageEditor's Pick:
Mixed outlook for trio of mining giantsEditor's Pick:
Glenstrata's just a silly word. Stick to big dividendsEditor's Pick:
Bulls should head for ChinaEditor's Pick:
George Godber’s AIM stock picks

